Is Now the Time to Buy This Blue-Chip Healthcare Stock?

Consistently meeting or beating analysts' revenue and earnings expectations is the sign of a quality stock. It demonstrates that its products and/or services have strong demand, which is indicative of a company with competitive advantages.

Diversified healthcare stock Abbott Laboratories (NYSE: ABT) has a track record of matching or exceeding analysts' revenue and earnings forecasts. But is the stock a buy for dividend growth investors? Let's dig into Abbott's fundamentals and valuation to address the question.

Image source: Getty Images.

Continue reading

Source Fool.com